Serous tubal intraepithelial carcinoma (STIC) – clinical impact and management
| Authors | |
|---|---|
| Year of publication | 2016 |
| Type | Article in Periodical |
| Magazine / Source | Expert Review of Anticancer Therapy |
| MU Faculty or unit | |
| Citation | |
| Doi | http://dx.doi.org/10.1080/14737140.2016.1247699 |
| Field | Gynaecology and obstetrics |
| Keywords | BRCA mutation; Fallopian tube; Ovarian carcinoma; Risk reducing salpingooophorectomy; Serous tubal intraepithelial carcinoma |
| Description | Introduction Serous tubal intraepithelial carcinoma (STIC) is most likely precursor lesion of the most part of high-grade serous pelvis carcinomas, carcinosarcoma and undifferentiated carcinoma with incidence of 0.6% to 7% in BRCA carriers or women with strong family history of breast or ovarian carcinoma. STIC is a pathomorphologically and immunohistochemically detectable lesion which biological significance and clinical relevance is unknown. Areas covered We investigate methods of STIC diagnostics and we present an overview of recent studies and available knowledge on surgical management, adjuvant chemotherapy and subsequent followup procedure in women with an isolated STIC. Expert commentary Patients found to have an incidental STIC lesion should be referred for screening of BRCA1/2 mutation. In absence of an invasive disease, follow-up of patient remains a reasonable choice. A rational scheme should include check-ups every 6 months consisting of gynecological examinations, CA 125 and/or HE4 and pelvic ultrasound examination by an expert sonographer. |